David Pyott has a wide background in the pharmaceutical industry, serving as CEO of Allergan, where he made significant changes for about 17 years. With a Master of Arts from the University of Edinburgh, he has spent over 30 years working in various roles, including heading the Novartis Nutrition Division. He was recently appointed to the board of Pliant Therapeutics in January 2021. Pyott is also involved in the boards of companies like Alnylam Pharmaceuticals and BioMarin Pharmaceutical. Beyond business, he holds honorary degrees and engages with educational foundations. In 2022, Pyott’s total compensation was nearly $11.2 million, with a blend of salary, bonuses, and stock options reflecting his performance and contribution. His experience shapes Pliant's vision, pushing healthcare and innovation forward.

Pliant TherapeuticsJanuary 2021 - November 2022

Current Market Cap

$775.19M

Number of Employees

158

Total Compensation

2021 - 2022

Trending up by 310.17% last year

Showing total compensation for the last 2021 - 2022

Stock

Up by 0.00% last year

Salary

Up by 9.73% last year

Bonus

Up by 4.50% last year

Other

Up by 339.68% last year

2022 2021

Year

2022

Total Compensation

$3.65M

Salary

$610.30K

Board Justification

The compensation philosophy is market-based, aligning cash compensation at or around the 50th percentile and equity compensation between 50th and 75th percentiles of the market data, enabling executive officers to share in the Company’s long-term success.

Bonus

$335.67K

Board Justification

Annual cash incentive based on corporate performance goals for 2023.

Other

$51.00K

Board Justification

Includes matching contributions under the 401(k) plan and personal travel reimbursements.

Restricted Stock

$2.65M(146.3K RSU)

Board Justification

RSUs granted under the 2020 Stock Option and Incentive Plan, vesting in three equal annual installments beginning January 16, 2023.

Performance Metrics

Performance metrics for 2023 included pre-clinical, clinical, regulatory, and program-related metrics (70% weight) and financial and operational metrics (30% weight).

SEC Filing

From April 26, 2023

View SEC Filing

David Pyott

Ex-CEO of Pliant Therapeutics

Education

Diploma in International and European Law from the University of Amsterdam; Honorary Degree in Medicine; Master of Arts degree from the University of Edinburgh; MBA from the London Business School

Field of Expertise

Born

January 1, 1957 - 67 years ago

Is Founder?

Tenure

1 year 10 months (Jan 2021 - Nov 2022)

Previous Experience

Chairperson and Chief Executive Officer of Allergan, Inc.; Head of Novartis Nutrition Division; Member of Executive Committee of Novartis AG

Predecessor

Neil Exter

January 2015 - November 2022

Successor

Thomas McCourt

March 2023 - June 2024